• 1. Structural insights into the ene-reductase synthesis of profens
  J. Waller,H. S. Toogood,V. Karuppiah,N. J. W. Rattray,D. J. Mansell,D. Leys,J. M. Gardiner,A. Fryszkowska,S. T. Ahmed,R. Bandichhor,G. P. Reddy,N. S. Scrutton Org. Biomol. Chem. 2017 15 4440

Comprehensive Analysis of Ibuprofen Impurity 1 (CAS No. 3585-47-5): Synthesis, Characterization, and Pharmaceutical Significance

In the realm of pharmaceutical quality control, Ibuprofen Impurity 1 (CAS 3585-47-5) has garnered significant attention as a critical process-related impurity in the manufacturing of the widely used NSAID, ibuprofen. This compound, chemically identified as 1-(4-isobutylphenyl)ethanol, is a key intermediate or byproduct during ibuprofen synthesis. With increasing regulatory scrutiny on drug purity standards—especially for over-the-counter medications—understanding this impurity's properties, analytical detection methods, and control strategies has become paramount for manufacturers and researchers alike.

The structural relationship between Ibuprofen Impurity 1 and the parent drug molecule makes it a frequent subject of pharmaceutical impurity profiling studies. Recent trends in ICH Q3A guidelines compliance have driven more laboratories to develop sensitive HPLC and LC-MS methods for its quantification at ppm levels. Notably, the 2023 USP updates on ibuprofen monographs explicitly reference this impurity, reflecting its regulatory importance. Analytical chemists often search for "CAS 3585-47-5 HPLC method" or "Ibuprofen related substances testing" when developing quality protocols.

From a synthetic chemistry perspective, 3585-47-5 typically forms during the carbonyl reduction step in ibuprofen production. Process chemists actively investigate "how to minimize Ibuprofen Impurity 1" through optimized catalytic conditions or alternative synthetic routes. Green chemistry initiatives have spurred interest in enzymatic approaches that potentially reduce this impurity's formation while improving overall process sustainability—a hot topic in pharmaceutical manufacturing optimization circles.

The thermal stability and polymorphic behavior of Ibuprofen Impurity 1 have become subjects of recent research, particularly regarding its potential impact on drug product stability. Stability-indicating methods capable of distinguishing this impurity from degradation products are frequently searched as "forced degradation studies for ibuprofen." These studies gain importance as regulatory agencies emphasize quality by design (QbD) principles throughout product lifecycles.

Advanced characterization techniques like NMR spectroscopy and X-ray crystallography have been employed to fully elucidate the structure of CAS 3585-47-5. Such data proves invaluable when addressing "ibuprofen impurity identification" challenges during method validation or regulatory submissions. The compound's chromatographic behavior under various pH conditions remains a common troubleshooting point for analysts, with many searching for "Ibuprofen Impurity 1 retention time" in reversed-phase systems.

Recent publications highlight the importance of genotoxic impurity assessment for Ibuprofen Impurity 1, though current data suggests it doesn't fall under this concerning category. This distinction makes it a valuable reference standard when establishing analytical method specificity for potentially more harmful impurities. Quality control laboratories often seek "ibuprofen impurity reference standards" to ensure accurate quantification during routine testing.

The pharmaceutical industry's shift toward continuous manufacturing has renewed interest in real-time monitoring of process impurities like 3585-47-5. PAT (Process Analytical Technology) approaches utilizing Raman spectroscopy or NIR probes are being explored to dynamically control impurity levels—a development frequently discussed in Industry 4.0 pharmaceutical applications. Such technological advancements address growing demands for both quality and manufacturing efficiency.

From a regulatory standpoint, the evolving thresholds for ICH identification thresholds have kept Ibuprofen Impurity 1 relevant in compliance discussions. Many quality professionals search for "ibuprofen impurity limits pharmacopeia" to stay updated with changing requirements across different markets. The compound serves as an excellent case study when examining regional differences in impurity control strategies between FDA, EMA, and other regulatory bodies.

In conclusion, Ibuprofen Impurity 1 (CAS 3585-47-5) represents more than just a quality control parameter—it embodies the pharmaceutical industry's ongoing challenges in balancing synthetic efficiency, analytical precision, and regulatory compliance. As ibuprofen maintains its position as one of the world's most consumed medications, understanding and controlling this impurity remains crucial for ensuring patient safety and product quality in an increasingly stringent global regulatory environment.

• 58560-75-1(Ibuprofen)
• 51146-56-6((S)-(+)-Ibuprofen)
• 66622-47-7(m-Isobutyl Ibuprofen)
• 51146-57-7((R)-(-)-Ibuprofen)
• 95499-72-2(2-methyl-2-4-(2-methylpropyl)phenylpropanoic acid)
• 3585-49-7(p-Butyl Ibuprofen)
• 404354-76-3((S)-2-(4-Butylphenyl)-propionic Acid)
• 139466-08-3(Profen)
• 121662-14-4(Ibuprofen-d)
• 15687-27-1(Ibuprofen)